Test Bank for Pharmacotherapeutics for Advanced Practice Nurse Prescribers Updated 2025–2026 Complete Exam Questions and Answers Study Guide for Advanced Practice Nursing Pharmacology Success

PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE NURSE PRESCRIBERS,QUESTIONS & T T T T T T TT



ANSWERS FULLY ANALYSED EDITION EXAM 100% CORRECTLY/VERIFIED ANSWERS WITH
T T T T T T T T TT



SATISFACTION GUARANTEED SUCCESS LATEST UPDATE 2023/2024 5TH EDITION WOO ROBINSON
T T T T T T T T T TT



TEST BANK GRADED A+
T T T




Chapter 1. T




An Introduction to Pharmacogenetics
T T T T




ANATASHI
Multiple Choice T




Identify the choice that best completes the statement or answers the question.
T T T T T T T T T T T




T 1. Genetic polymorphisms account for differences in metabolism, including:
T T T T T T T T




1. Poor metabolizers, who lack a working enzyme
T T T T T T




2. Intermediate metabolizers, who have one working, wild-type allele and one mutant T T T T T T T T T T




3. Extensive metabolizers, with two normally functioning alleles T T T T T T




4. All of the above T T T




T 2. Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
T T T T T T T T T T T




1. A need to monitor drugs metabolized by 2D6 for toxicity
T T T T T T T T T




2. Increased dosages needed of drugs metabolized by 2D6, such as the T T T T T T T T T T TT




selective serotoreuptake inhibitors T T




3. Decreased conversion of codeine to morphine by CYP 2D6 T T T T T T T T




4. The need for lowered dosages of drugs, such as beta blockers
T T T T T T T T T T




T 3. Rifampin is a nonspecific CYP450 inducer that may:
T T T T T T T T




1. Lead to toxic levels of rifampin and must be monitored closely
T T T T T T T T T T




2. Cause toxic levels of drugs, such as oral contraceptives, when coadministered
T T T T T T T T T T




3. Induce the metabolism of drugs, such as oral contraceptives, leading to therapeutic
T T T T T T T T T T T




4. Cause nonspecific changes in drug metabolism
T T T T T
A
T 4. Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
T T T T T T T T T T T T




1. Decreased therapeutic levels of quinidine T T T T




2. Increased therapeutic levels of quinidine T T T T




3. Decreased levels of a coadministered drug, such as digoxin, that T T T T T T T T T T




requires P-glycoprabsorption and elimination T T T




4. Increased levels of a coadministered drug, such as digoxin, that T T T T T T T T T TT




requires P-glycoproabsorption and elimination T T T




T 5. Warfarin resistance may be seen in patients with VCORC1 mutation, leading to:
T T T T T T T T T T T T




1. Toxic levels of warfarin building upT T T T T

, 2. Decreased response to warfarin
T T T




3. Increased risk for significant drug interactions with warfarin
T T T T T T T




4. Less risk of drug interactions with warfarin
T T T T T T




T 6. Genetic testing for VCORC1 mutation to assess potential warfarin
T T T T T T T T T T




resistance is requiredprior to prescribing warfarin.
T T T T T




1. True
2. False

T 7. Pharmacogenetic testing is required by the U.S. Food and Drug
T T T T T T T T T T T




Administration prior toprescribing: T T




1. Erythromycin
2. Digoxin
3. Cetuximab

, 4. Rifampin

T 8. Carbamazepine has a Black Box Warning recommending testing for the
T T T T T T T T T T T




HLA-B*1502 allelein patients with Asian ancestry prior to starting
T T T T T T T T T




therapy due to: T T




1. Decreased effectiveness of carbamazepine in treating seizures in Asian patients wit
T T T T T T T T T T T




HLA-B*1502 allele T




ANATASHI
2. Increased risk for drug interactions in Asian patients with the HLA-B*1502 allele
T T T T T T T T T T T




3. Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-B*1502 a
T T T T T T T T T T




4. Patients who have the HLA-B*1502 allele being more likely to
T T T T T T T T T T




have a resistance tocarbamazepine
T T T




T 9. A genetic variation in how the metabolite of the cancer drug
T T T T T T T T T T T T




irinotecan SN-38 isinactivated by the body may lead to:
T T T T T T T T




1. Decreased effectiveness of irinotecan in the treatment of cancer
T T T T T T T T




2. Increased adverse drug reactions, such as neutropenia T T T T T T




3. Delayed metabolism of the prodrug irinotecan into the active metabolite SN-38
T T T T T T T T T T




4. Increased concerns for irinotecan being carcinogenic T T T T T




10. Patients who have a poor metabolism phenotype will have:
T T T T T T T T T T




1. Slowed metabolism of a prodrug into an active drug, leading to accumulation of pr
T T T T T T T T T T T T T




2. Accumulation of inactive metabolites of drugs T T T T T




3. A need for increased dosages of medications
T T T T T T




4. Increased elimination of an active drug T T T T T




11. Ultra-rapid metabolizers of drugs may have:
T T T T T T T




1. To have dosages of drugs adjusted downward to prevent drug accumulation
T T T T T T T T T T




2. Active drug rapidly metabolized into inactive metabolites, leading
T T T T T T T TT




to potential therafailure
T T
A
3. Increased elimination of active, nonmetabolized drug T T T T T




4. Slowed metabolism of a prodrug into an active drug, leading to an accumulation of
T T T T T T T T T T T T T




12. A provider may consider testing for CYP2D6 variants prior to
T T T T T T T T T T T T




starting tamoxifen forbreast cancer to:
T T T T




1. Ensure the patient will not have increased adverse drug reactions to the tamoxifen
T T T T T T T T T T T T




2. Identify potential drug-drug interactions that may occur with tamoxifen
T T T T T T T T




3. Reduce the likelihood of therapeutic failure with tamoxifen treatment
T T T T T T T T




4. Identify poor metabolizers of tamoxifen T T T T

, Chapter 1. An Introduction to
T T T T T




PharmacogeneticsAnswer Section
T




MULTIPLE CHOICE T




1. ANS:
T 4 PTS: 1
2. ANS:
T 2 PTS: 1
3. ANS:
T 3 PTS: 1
4. ANS:
T 4 PTS: 1
5. ANS:
T 2 PTS: 1
6. ANS:
T 2 PTS: 1
7. ANS:
T 3 PTS: 1
8. ANS:
T 3 PTS: 1
9. ANS:
T 2 PTS: 1
10. 1 PTS: 1
ANS:
11. 2 PTS: 1
ANS:
12. 3 PTS: 1
ANS: